TIZIANA LIFE SCIENCES LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.7801 USD | -7.25% |
|
+17.13% | +39.30% |
| 04-23 | Sector Update: Health Care Stocks Rise in Afternoon Trading | MT |
| 04-23 | Tiziana Life Sciences Says US FDA Allows Enrollment of 20 More Patients in Foralumab MS Expanded Access Program | MT |
| Sales 2021 | - | Sales 2022 | - | Capitalization | 60.66M 4.86B |
|---|---|---|---|---|---|
| Net income 2021 | -23M -1.84B | Net income 2022 | -15M -1.2B | EV / Sales 2021 | - |
| Net cash position 2021 | 42.19M 3.38B | Net cash position 2022 | 17.76M 1.42B | EV / Sales 2022 | - |
| P/E ratio 2021 |
-4.01
x | P/E ratio 2022 |
-3.95
x | Employees | 9 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 32.56% |
More Fundamentals
* Assessed data
More news
Latest transcript on Tiziana Life Sciences Ltd
More press releases
| 1 day | -7.25% | ||
| 1 week | +17.13% | ||
| Current month | +71.83% | ||
| 1 month | +87.07% | ||
| 3 months | +39.90% | ||
| 6 months | +23.83% | ||
| Current year | +39.30% |
1 week
0.67
0.89
1 month
0.410.89
Current year
0.410.89
1 year
0.411.27
3 years
0.411.70
5 years
0.411.70
10 years
0.411.70
| Managers | Title | Age | Since |
|---|---|---|---|
Gabriele Cerrone
CEO | Chief Executive Officer | 52 | 10/02/98 |
Keeren Shah
DFI | Director of Finance/CFO | 47 | - |
Vaseem Palejwala
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/16 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
John Brancaccio
BRD | Director/Board Member | 76 | 30/06/20 |
Willy Simon
BRD | Director/Board Member | 72 | 31/10/15 |
Gabriele Cerrone
CEO | Chief Executive Officer | 52 | 10/02/98 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 0.7801 | -7.25% | 252,821 |
| 25/04/24 | 0.8411 | +6.45% | 889,692 |
| 24/04/24 | 0.7901 | +1.95% | 335,885 |
| 23/04/24 | 0.775 | +2.84% | 2,513,051 |
| 22/04/24 | 0.7536 | +13.15% | 550,057 |
Delayed Quote Nasdaq, April 26, 2024 at 09:30 pm
More quotes
Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company. The Company develops transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Crohn's Disease and KRAS+ NSCLC. Its pipeline candidates include Foralumab (TZLS-401), Anti IL-6R mAb (TZLS-501) and Milciclib (TZLS-201). Foralumab (TZLS-401) is a fully human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohnâs and neurodegenerative diseases. Its Anti IL-6R mAb (TZLS-501), a fully human mAb binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune disease and cancer, reducing circulating levels of the IL-6 cytokine. Milciclib is a potent, small molecule inhibitor of multiple cyclin-dependent kinases (CDKs), tropomycinreceptor kinases and Src family kinases controlling cell growth and malignant progression of cancer.
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +39.30% | 78.25M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- TLSA Stock
